Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
NCT02503501Phase 2Terminated
- Sponsor
- HealthPartners Institute
- Start
- Sep 2015
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of insulin glulisine in Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), sponsored by HealthPartners Institute. Started Sep 2015; status: terminated.
02
Drugs
insulin glulisine
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02503501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503501.